TY - JOUR
T1 - Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization
AU - Chu, Lisa W.
AU - Pettaway, Curtis A.
AU - Liang, Jan C.
N1 - Funding Information:
We thank Ms. Vicki Hopwood for the use of the CGH digital image analysis system. This study was supported in part by grant R21 CA67964 by the National Cancer Institute and grant #030813 by the Robert Wood Johnson Foundation awarded to J.C.L. and C.A.P., respectively.
PY - 2001
Y1 - 2001
N2 - Established recently are two in vivo prostate tumor progression models in which subclones of the PC3M and LNCaP cell lines were selected for varying growth characteristics and metastatic potential after successive orthotopic implantation in the prostate of nude mice. In this study, we used comparative genomic hybridization (CGH) to compare the chromosomal abnormalities between the parental cell lines and their respective variants and to determine if specific chromosomal abnormalities can be identified that are associated with different growth properties. PC3M and its derivative cell lines PC3M-Pro4 and PC3M-LN4 shared gains of 8q22-qter, 10q21-q22, and Xq27-qter and loss of 13q33-qter. PC3M-Pro4, a derivative line that produced significantly larger tumors in the prostate, had a unique gain of 3q13. In contrast, PC3M-LN4, the derivative line that produced significantly larger metastatic tumors in the lymph nodes and had higher incidences of distant metastases, had a specific gain of 1q21-q22 and losses of 10q23-qter and 18q12-q21. In the second in vivo model, LNCaP and its derivative cell lines shared gain of 3q27-qter and loss on 13q21-qter. The derivative line that produced significantly larger tumors in the prostate, LNCaP-Pro5, had a unique gain on 13q12-q13. In comparison, LNCaP-LN3, a derivative line that had a significantly higher incidence of lymph node metastases and produced significantly larger metastatic tumors in the lymph nodes, had specific losses of 16q23-qter and 21q. Interestingly, some regions of loss (e.g., 10q23→qter, 16q23→qter, and 18q12→q21) detected in the variant cell lines correlated well with abnormalities seen in clinical prostate cancer cases. Thus, our data suggest not only that these cell lines are relevant in vivo models for prostate cancer progression, but also that CGH is a valuable tool for uncovering chromosomal regions that are important for aggressive growth and metastsis of prostate cancer cells.
AB - Established recently are two in vivo prostate tumor progression models in which subclones of the PC3M and LNCaP cell lines were selected for varying growth characteristics and metastatic potential after successive orthotopic implantation in the prostate of nude mice. In this study, we used comparative genomic hybridization (CGH) to compare the chromosomal abnormalities between the parental cell lines and their respective variants and to determine if specific chromosomal abnormalities can be identified that are associated with different growth properties. PC3M and its derivative cell lines PC3M-Pro4 and PC3M-LN4 shared gains of 8q22-qter, 10q21-q22, and Xq27-qter and loss of 13q33-qter. PC3M-Pro4, a derivative line that produced significantly larger tumors in the prostate, had a unique gain of 3q13. In contrast, PC3M-LN4, the derivative line that produced significantly larger metastatic tumors in the lymph nodes and had higher incidences of distant metastases, had a specific gain of 1q21-q22 and losses of 10q23-qter and 18q12-q21. In the second in vivo model, LNCaP and its derivative cell lines shared gain of 3q27-qter and loss on 13q21-qter. The derivative line that produced significantly larger tumors in the prostate, LNCaP-Pro5, had a unique gain on 13q12-q13. In comparison, LNCaP-LN3, a derivative line that had a significantly higher incidence of lymph node metastases and produced significantly larger metastatic tumors in the lymph nodes, had specific losses of 16q23-qter and 21q. Interestingly, some regions of loss (e.g., 10q23→qter, 16q23→qter, and 18q12→q21) detected in the variant cell lines correlated well with abnormalities seen in clinical prostate cancer cases. Thus, our data suggest not only that these cell lines are relevant in vivo models for prostate cancer progression, but also that CGH is a valuable tool for uncovering chromosomal regions that are important for aggressive growth and metastsis of prostate cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=0034967663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034967663&partnerID=8YFLogxK
U2 - 10.1016/S0165-4608(01)00389-2
DO - 10.1016/S0165-4608(01)00389-2
M3 - Article
C2 - 11425457
AN - SCOPUS:0034967663
SN - 0165-4608
VL - 127
SP - 161
EP - 167
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
IS - 2
ER -